Literature DB >> 10744049

HeLa cell transformants overproducing mouse metallothionein show in vivo resistance to cis-platinum in nude mice.

H Toyoda1, T Mizushima, M Satoh, N Iizuka, A Nomoto, H Chiba, M Mita, A Naganuma, S Himeno, N Imura.   

Abstract

Plasmid pSV2MT-I encoding mouse metallothionein-I (MT-I) designed to be expressed under the control of an SV40 promoter was introduced into human HeLa S3 cells. Several transformants (HeLa/MTH) carrying multi-copies of mouse MT-I cDNA in their genomes were isolated. These transformants produced 4 to 20-fold larger amounts of MT than their parent cells. The MT levels in HeLa/MTH were well correlated with the extent of resistance to cadmium, but not with that to cis-platinum (cis-DDP) in vitro. To study the role of MT in resistance to cis-DDP in vivo, nude mice were inoculated subcutaneously with two independent HeLa/MTH clones. MT levels in these tumors were about 3-fold higher than those in the parental cells. The growth of tumors derived from either HeLa/MTH clone was not inhibited in the presence of 15 micromol/kg of cis-DDP, which completely inhibited the growth of tumors derived from the parental HeLa cells. These data strongly suggest that the elevated level of MT confers resistance to cis-DDP in vivo but not in vitro. Thus, the results of this study indicate that in vitro determinations of the influence of MT on cis-DDP resistance may underestimate its importance in in vivo situations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744049      PMCID: PMC5926218          DOI: 10.1111/j.1349-7006.2000.tb00864.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  41 in total

1.  Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein.

Authors:  J Koropatnick; J Pearson
Journal:  Mol Pharmacol       Date:  1993-07       Impact factor: 4.436

2.  Isolation and characterization of the mouse metallothionein-I gene.

Authors:  D M Durnam; F Perrin; F Gannon; R D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

3.  Binding of glutathione-depleting agents to metallothionein.

Authors:  S Z Cagen; C D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  1980-06-30       Impact factor: 4.219

4.  Comparison of methods for estimating hepatic metallothionein in rats.

Authors:  F N Kotsonis; C D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  1977-12       Impact factor: 4.219

5.  Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor.

Authors:  N Satomi; A Sakurai; R Haranaka; K Haranaka
Journal:  J Biol Response Mod       Date:  1988-02

6.  Chemotherapy of human tumor xenografts in genetically athymic mice.

Authors:  A A Ovejera; D P Houchens; A D Barker
Journal:  Ann Clin Lab Sci       Date:  1978 Jan-Feb       Impact factor: 1.256

7.  Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis.

Authors:  M Satoh; D M Kloth; S A Kadhim; J L Chin; A Naganuma; N Imura; M G Cherian
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

8.  Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents.

Authors:  B Kaina; H Lohrer; M Karin; P Herrlich
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

9.  Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.

Authors:  R J Schilder; L Hall; A Monks; L M Handel; A J Fornace; R F Ozols; A T Fojo; T C Hamilton
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

10.  Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents.

Authors:  H Lohrer; T Robson
Journal:  Carcinogenesis       Date:  1989-12       Impact factor: 4.944

View more
  3 in total

1.  Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.

Authors:  Paweł Surowiak; Verena Materna; Irina Kaplenko; Marek Spaczyński; Manfred Dietel; Hermann Lage; Maciej Zabel
Journal:  Virchows Arch       Date:  2005-06-21       Impact factor: 4.064

Review 2.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

3.  Cytotoxicity of ICD-85 NPs on Human Cervical Carcinoma HeLa Cells through Caspase-8 Mediated Pathway.

Authors:  Saeed Moradhaseli; Abbas Zare Mirakabadi; Ali Sarzaeem; Morteza Kamalzadeh; Reza Haji Hosseini
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.